Compare CDMOs with mRNA manufacturing capabilities for vaccines, therapeutics, and gene editing applications. Filter by scale, LNP formulation expertise, and regulatory track record.
mRNA manufacturing involves enzymatic in vitro transcription (IVT) to produce the mRNA molecule, followed by purification and formulation into lipid nanoparticles (LNPs) for delivery. The COVID-19 pandemic validated mRNA as a manufacturing platform, and now hundreds of mRNA programs are in development for infectious diseases, oncology, rare diseases, and protein replacement therapies.
The manufacturing process is cell-free, which is a fundamental advantage over traditional biologics. No cell culture or fermentation is required -- mRNA is synthesized enzymatically from a DNA template, purified chromatographically, and encapsulated in LNPs. This enables rapid campaign switching and shorter manufacturing timelines compared to monoclonal antibodies or viral vectors.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.